Xencor Inc. Daily Stock Analysis

Daily Stock Analysis, XNCR, Xencor Inc, priceseries

Xencor Inc. Daily Stock Analysis
Stock Information
Open
28.67
Close
28.29
High
28.99
Low
28.19
Previous Close
28.59
Daily Price Gain
-0.30
YTD High
42.30
YTD High Date
Jan 4, 2022
YTD Low
28.19
YTD Low Date
Mar 7, 2022
YTD Price Change
-13.34
YTD Gain
-32.04%
52 Week High
47.44
52 Week High Date
Mar 22, 2021
52 Week Low
28.19
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-14.71
52 Week Gain
-34.21%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 20. 2017
23.15
May 2. 2017
24.78
8 Trading Days
7.06%
Link
LONG
Jul 3. 2017
21.51
Jul 20. 2017
23.14
12 Trading Days
7.57%
Link
LONG
Feb 13. 2018
22.81
Mar 14. 2018
30.94
20 Trading Days
35.65%
Link
LONG
Jun 17. 2019
32.55
Jul 25. 2019
44.36
27 Trading Days
36.27%
Link
LONG
Nov 12. 2019
34.77
Dec 10. 2019
39.90
19 Trading Days
14.77%
Link
LONG
Mar 19. 2020
27.98
Mar 20. 2020
29.81
1 Trading Days
6.56%
Link
LONG
Aug 12. 2020
32.53
Aug 28. 2020
35.01
12 Trading Days
7.63%
Link
LONG
Dec 8. 2020
41.30
Dec 29. 2020
44.34
14 Trading Days
7.35%
Link
LONG
Oct 4. 2021
35.52
Oct 18. 2021
37.38
10 Trading Days
5.25%
Link
Company Information
Stock Symbol
XNCR
Exchange
NasdaqGM
Company URL
http://www.xencor.com
Company Phone
626-305-5900
CEO
Bassil I. Dahiyat
Headquarters
California
Business Address
111 WEST LEMON AVE, MONROVIA, CA 91016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001326732
About

Xencor, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It uses proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, asthma, cancer, and other conditions. The company was founded Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Description

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading